INTERCEPT PHARMACEUTICALS, INC. (747-304)

By June 19, 2019 Active/Enrolling
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis

Leave a Reply